#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / General Practitioner / 2021 - 2

Hepatotoxic potential of nutritional and dietary supplements

Czech version

Authors: M. Jakabovičová 1;  Z. Ďurkovičová 1;  M. Ondrejkovičová 2;  X. Faktorová 1;  V. Mojto 1;  M. Szántová 1
Authors‘ workplace: Lekárska fakulta UK v Bratislave a Univerzitná nemocnica v Bratislave, Nemocnica akademika Ladislava Dérera, III. interná klinika LF UK a UNB, Prednosta: doc. MUDr. Viliam Mojto, CSc., MPH, MHA 1;  Gastroenterologická klinika Slovenskej zdravotníckej univerzity a Univerzitná nemocnica v Bratislave, Prednosta: doc. MUDr. Marian Bátovský, CSc. 2
Published in: Prakt. Lék. 2021; 101(2): 87-96
Category: Reviews

Overview

The growing trend in the consumption of herbal and dietary supplements is associated with increasing hepatotoxicity. Compared to conventional drugs, herbal and dietary supplements are a more common cause of acute liver failure. In addition, they can cause various types of damage ranging from hepatitis through hepatic fibrosis and steatosis to hepatic failure, cirrhosis, tumours, and death. They predominantly affect the female sex. In contrast to drug-induced hepatotoxicity, they more often cause a hepatocellular type of liver injury with markedly elevated transaminases, a more severe course, and more frequent unintentional rechallenge. In the United States, they account for 20% of all cases of hepatotoxicity. The paper provides an up-to-date review of the risks of herbal and dietary supplements with many clinical and research challenges in the diagnosis and identification of responsible constituents, treatment, and prevention. Compared to herbal products, patient compliance with pharmacotherapy is often different in favour of herbal products and dietary supplements. The myth of the safety of natural remedies is refuted by hepatotoxicity based on research data. Correction is possible only by comprehensive education of the professional public and awareness of potential risks.

Keywords:

herbal hepatotoxicity – Herb-Induced Liver Injury (HILI) – Herbal and Dietary Supplements (HDS) – epidemiology – RUCAM

Sources
  1. Teschke R.Traditional Chinese medicine induced liver injury. J Clin Transl Hepatol 2014; 2: 80–94.
  2. Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003–2006. J Nutr 2011; 141(2): 261–266.
  3. Reinert A, Rohrmann S, Becker N, et al. Lifestyle and diet in people using dietary supplements: a German cohort study. Eur J Nutr. 2007; 46: 165–173.
  4. US Food and Drug Administration. FDA initiates new online reporting method for dietary supplement adverse events to facilitate reporting [online]. Dostupné z: http://wayback.archive-it.org/7993/20171114120314/https://www.fda.gov/Food/NewsEvents/ConstituentUpdates/ucm381317.htm [cit. 2021-02-14].
  5. Navarro V, Khan I, Bjornsson E. Liver injury from herbal and dietary supplements. Hepatology 2017; 65(1): 363–373.
  6. Bjornsson ES. Drug-induced liver injury: an overview over the most critical compound. Arch Toxicol 2015; 89: 327–334.
  7. Pantano F, Mannocchi G, Marinelli E, et al. Hepatotoxicity induced by Greater Celandine (Chelidonium majus L.): A review of the literature. Eur Rev Med Pharmacol Sci 2017; 21: 2146–2152.
  8. Zhu J, Seo JE, Wang S, et al. The development of a database for herbal and dietary supplement induced liver toxicity. Int J Mol Sci 2018; 19(10): 2955.
  9. Grewal P, Ahmad J. Severe liver injury due to herbal and dietary supplements and the role of liver transplantation. World J Gastroenterol 2019; 25(46): 6704–6712.
  10. Rashrash M, Schommer JC, Brown LM. Prevalence and predictors of herbal medicine use among adults in the United States. J Patient Exp 2017; 4(3): 108–113.
  11. Andrade RJ, Robles M, Ulzurrun E, et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10(9): 1467–1487.
  12. Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144: 1419–1425.
  13. Inmaculada MC, Miren GC, Andres GJ, et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI registry. Clin Gastroenterol Hepatol 2018; 16(9): 1495–1502.
  14. Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment against cirrhosis (HALT-C) Trial. Hepatology 2008; 47(2): 605–612.
  15. Navarro V, Avula B, Khan I, et al. The contents of herbal and dietary supplements implicated in liver injury in the United States are frequently mislabeled. Hepatol Commun. 2019; 3(6): 792–794.
  16. Rahnema CD, Crosnoe LE, Kim ED. Designer steroids over the counter supplements and their androgenic component: review of an increasing problem. Andrology 2015; 3: 150–155.
  17. Afolabi SO, Akindele AJ, Awodele O, et al. A 90 day chronic toxicity study of Nigerian herbal preparation DAS-77 in rats. BMC Complemen Altern Med 2012; 12(1): 79.
  18. Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN prospective study. Gastroenterology 2015; 148: 1340–1352.
  19. Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014; 60: 1399–1408.
  20. Reuben A, Koch DG, Lee WM, et al. Drug‐induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065–2078. 
  21. Andrade RJ. Landscape of liver injury from HDS in Europe, Latin America and Asia. Clin Liver Dis 2019; 14(2): 49–50.
  22. Takikawa H, Murata Y, Horiike N, et al. Drug-induced liver injury in Japan: An analysis of 1676 cases between 1997 and 2006. Hepatol Res 2009; 39: 427–431.
  23. Zhou Y, Yang L, Liao Z, et al. Epidemiology of drug-induced liver injury in China: A systematic analysis of the Chinese literature including 21,789 patients. Eur J Gastroenterol Hepatol 2013; 25: 825–829.
  24. Wai CT, Tan BH, Chan CL, et al. Drug-induced liver injury at an Asian center: A prospective study. Liver Int 2007; 27: 465–474.
  25. Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012; 107: 1380–1387.
  26. Andrade RJ, Robles M, Ulzurrun E, et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009; 10(9): 1467–1487.
  27. Saper RB, Phillips RS, Sehgal A, et al. Lead, mercury, and arsenic in US- and Indian-manufactured ayurvedic medicines sold via the Internet. JAMA 2008; 300(8): 915–923.
  28. Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 2019; 156(8): 2230–2241.
  29. Cho JH, Oh DS, Hon SH, et al. A nationwide study of the incidence rate of herb-induced liver injury in Korea. Arch Toxicol 2017; 91(12): 4009–4015.
  30. Byeon JH, Kil JH, Ahn YC, et al. Systematic review of published data on herb induced liver injury. J Ethnopharmacol 2019; 233: 190–196.
  31. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990–97. JAMA 1998; 280(18): 1569–1575. 
  32. Izzo A, Ernst E. Interactions between herbal medicines and prescribed drugs an updated systematic review. Drugs 2009; 69(13): 1777–1798.
  33. Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over 10-years period. Gastroenterology 2005; 129(2): 512–521.
  34. Andrade RJ, Caliz IM, Jimenez GA, et al. Hepatic damage by natural remedies. Semin Liver Dis 2018; 38(1): 21–40.
  35. Rossi S, Navarro V. Herbs and liver injury: A clinical perspective. Clin Gastroenterol Hepatol 2014; 12: 1069–1076.
  36. Szántová M, Sedlačko J, Jakabovičová M. Lieková a herbálna hepatotoxicita: Prehľad klinických klasifikácií. Vnitř. Lék. 2018; 64(4): 384–393.
  37. Neuman MG, Cohen LB, Opris M, et al. Hepatotoxicity of pyrrolizidine alkaloids. J Pharm Pharm Sci 2015; 18(4): 825–843.
  38. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009; 51(2): 237–267.
  39. Verma S, Thuluvath PJ. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 2007; 5(4): 408–416.
  40. EASL Clinical Practice Guidelines: Drug-induce liver injury. J Hepatol 2019; 70(6): 1222–1261.
  41. http:/www.LiverTox.nih.gov
Labels
General practitioner for children and adolescents General practitioner for adults
History of infections – never ending story
A vegan patient: nutritional characteristic of plant-based diet
Optical endoscopic methods in the diagnostics of head and neck tumours
Occupational diseases reported in the Czech Republic in 2020
Knowledge of nurses of disinfection of selected objects and surfaces in the provision of health services
Algorithm for differential diagnosis of urological symptoms in primary health care
Zlatá medaile České lékařské společnosti J. E. Purkyně prof. MUDr. Zdeňku Mračkovi
Article was published in

General Practitioner

Issue 2
2021 Issue 2
Most read in this issue
Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#